STOCK TITAN
  1. Home
  2. News
  3. ixhl

Incannex Healthcare Limited American Depositary Shares - IXHL STOCK NEWS

Welcome to our dedicated page for Incannex Healthcare American Depositary Shares news (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare American Depositary Shares stock.

Incannex Healthcare Limited (Nasdaq: IXHL) is a clinical stage pharmaceutical company dedicated to developing innovative medical cannabis products for the treatment of several major health conditions, including Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company holds an Australian license to import, export, and distribute medicinal cannabis products and has launched a diverse line of cannabinoid-based products.

Incannex recently announced the commencement of patient dosing in a Phase 2 clinical trial for their proprietary combination drug candidate, IHL-675A. This drug, composed of Hydroxychloroquine Sulphate (HCQ) and cannabidiol (CBD), is designed to treat rheumatoid arthritis (RA). The trial aims to measure pain and function improvement over a 24-week period using the RAPID-3 assessment. 128 participants across 10 study sites in Australia will be part of this double-blind study, with some receiving IHL-675A, CBD, HCQ, or a placebo.

Chief Scientific Officer Dr. Mark Bleackley highlighted the trial as a significant milestone, emphasizing that RA affects millions globally and that IHL-675A has the potential to meet unmet needs in this area. The trial includes regular monitoring through blood tests, physical exams, and MRI scans to assess joint inflammation and damage.

Previously, in 2022 and 2023, Incannex successfully conducted a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of IHL-675A. The results showed that the drug was well tolerated with no serious adverse events, indicating its potential as a viable treatment option. Interestingly, the trial pointed out that the uptake of CBD in IHL-675A might be faster than the reference drug Epidiolex, while the uptake of HCQ might be slower compared to Plaquenil. This could offer patients quicker relief from inflammation and extended relief from pain.

Through their ongoing projects and trials, Incannex Healthcare is positioning itself as a leader in the pharmaceutical industry, focusing on the potential benefits of cannabinoids and psychedelic medicine therapies for unmet medical needs.

For more detailed information, visit the official Incannex website or follow the latest news updates related to the company's progress and innovations.

News

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) announces positive Phase 2 results for psilocybin in generalised anxiety disorder. The PsiGAD1 trial achieved its primary endpoint with a significant HAM-A reduction of 12.8 points, surpassing expectations. Psilocybin group showed 44% improvement and 27% remission rate, far exceeding placebo. Psilocybin was well-tolerated with no severe adverse events. IND application for Phase 2B trial submitted to FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.58%
Tags
clinical trial
-
News

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) successfully completes pre-IND meeting with the FDA for CannQuit-N, a tobacco smoking cessation drug, receiving positive feedback and guidance for clinical trial design and manufacturing strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none
-
News

Clarion Clinics Open for Psychedelic-Assisted Treatments

Rhea-AI Summary
Incannex Healthcare Inc (Nasdaq: IXHL) is pleased to announce that Clarion Clinic’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression. The clinic in Melbourne is now open and represents Australia’s leading track record in psychedelic-assisted therapies. The TGA down-scheduled MDMA and psilocybin for use in the treatment of PTSD and TRD, permitting their use in clinical service delivery through the Authorised Prescriber Scheme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
none
News

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has announced the commencement of patient dosing in the Phase 2 clinical trial for IHL-675A, a combination drug candidate for rheumatoid arthritis. The trial aims to assess pain and function relative to baseline and will enroll 128 participants across 10 study sites in Australia. IHL-675A is a proprietary combination of Hydroxychloroquine Sulphate and cannabidiol, with well-characterized anti-inflammatory activity. The trial will monitor safety and efficacy outcomes, including inflammatory biomarkers and joint inflammation and damage via MRI. IHL-675A is a potential treatment for other inflammatory conditions such as inflammatory bowel disease, COPD, and asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
clinical trial
-
News

Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences

Rhea-AI Summary
Incannex Healthcare Inc. completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial evaluating its psilocybin treatment program for patients with generalized anxiety disorder. The company anticipates topline results within Q1 2024 and is well-advanced in the FDA IND application process. An independent documentary covering Monash Clinical Psychedelic Lab and PsiGAD research program will be released by SBS television network in late February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
clinical trial
-
News

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has received IRB approval for the protocol of its Phase 2/3 clinical trial for the drug candidate IHL-42X to treat obstructive sleep apnea (OSA). The trial will assess safety and efficacy in OSA patients who are intolerant, non-compliant, or naïve to positive airway pressure (PAP). The study aims to recruit at least 560 patients across the United States, Germany, Spain, and Finland. The Phase 2/3 trial has already begun startup with 24 sites selected in the United States, 13 in Germany, 4 in Spain, and 2 in Finland. IHL-42X has shown promising results in a Phase 2 proof-of-concept study, reducing the apnea hypopnea index (AHI) by over 50% at the optimal dose, improving oxygen desaturation index, sleep efficiency, and patient-reported sleep quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
News

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Rhea-AI Summary
Incannex Healthcare Ltd (Nasdaq: IXHL) has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. The Melbourne clinic fit-out is complete, and the clinical and administrative teams are in place. The clinic is the first dedicated Psychedelic-assisted therapy clinic in Australia and has received a substantial number of expressions of interest in treatment submissions from potential patients since opening its application process earlier this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) is developing IHL-42X, a promising drug candidate for obstructive sleep apnea (OSA) treatment. The drug has shown significant efficacy in reducing apnea hypopnea index (AHI) in Phase 2 clinical trials, with potential to address a market of 936 million affected adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.45%
Tags
clinical trial
-
News

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Rhea-AI Summary
Incannex Healthcare Inc. (NASDAQ: IXHL) successfully completed its redomiciliation from Australia to the United States, with shares of common stock expected to commence trading on Nasdaq under the symbol 'IXHL' on November 30, 2023. The company will now be subject to the reporting requirements of the SEC and corporate governance rules of Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC

Rhea-AI Summary
Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) announces the approval of the scheme of arrangement for the proposed re-domiciliation from Australia to the United States. The Federal Court of Australia has made orders approving the scheme, with Incannex Healthcare Inc. becoming the ultimate parent company. The company has applied to suspend quotation and trading of shares on ASX, with ADRs continuing to trade on Nasdaq until the implementation date. Shareholders and optionholders will be entitled to receive the Scheme consideration on the implementation date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.28%
Tags
none

FAQ

What is the current stock price of Incannex Healthcare American Depositary Shares (ixhl)?

The current stock price of Incannex Healthcare American Depositary Shares (ixhl) is $2.44 as of November 4, 2024.

What is the market cap of Incannex Healthcare American Depositary Shares (ixhl)?

The market cap of Incannex Healthcare American Depositary Shares (ixhl) is approximately 46.8M.

What does Incannex Healthcare Limited do?

Incannex Healthcare Limited is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of conditions such as OSA, TBI/Concussion, RA, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

What is IHL-675A?

IHL-675A is Incannex's proprietary combination drug candidate composed of Hydroxychloroquine Sulphate (HCQ) and cannabidiol (CBD), currently in Phase 2 clinical trials for rheumatoid arthritis.

What conditions is Incannex focusing on?

Incannex focuses on treating Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

How is Incannex Healthcare positioned in the pharmaceutical industry?

Incannex Healthcare is positioned as an innovative leader in the pharmaceutical industry, focusing on the therapeutic benefits of cannabinoids and psychedelic medicine therapies for unmet medical needs.

What was the outcome of the Phase 1 clinical trial for IHL-675A?

The Phase 1 clinical trial for IHL-675A indicated that the drug was well tolerated with no serious adverse events, showing promising results for its safety and potential efficacy.

Where is Incannex Healthcare based?

Incannex Healthcare operates out of Melbourne, Australia, and has a presence in New York, USA.

What makes IHL-675A unique?

IHL-675A combines the anti-inflammatory properties of Hydroxychloroquine Sulphate (HCQ) and cannabidiol (CBD), potentially offering rapid and extended relief from inflammation and pain.

How can I invest in Incannex Healthcare Limited?

Investors can purchase shares of Incannex Healthcare Limited under the Nasdaq symbol IXHL.

What are the future plans for IHL-675A?

Future plans for IHL-675A include completing the Phase 2 clinical trial and submitting data for regulatory approval, including contributing to the FDA 505(b)2 new drug application dossier.

Who should consider IHL-675A as a treatment option?

IHL-675A is being developed for patients suffering from rheumatoid arthritis and potentially other inflammatory conditions such as inflammatory bowel disease and chronic obstructive pulmonary disease (COPD).

Stock IXHL logo
Incannex Healthcare Limited American Depositary Shares

Nasdaq:IXHL

IXHL Rankings

#4869 Ranked by Market Cap
N/A Ranked by Dividends

IXHL Stock Data

46.75M
17.64M
25.3%
4.86%
0.4%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DOCKLANDS, VICTORIA